News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Eisai Inc. (ESALF.PK)’s Perampanel Didn’t Significantly Reduce Epileptic Seizures in Study


4/14/2011 10:51:42 AM

Bloomberg -- Eisai Co.’s experimental epilepsy drug didn’t cut seizure rates significantly more than a placebo in patients who didn’t improve on previous treatments, a researcher said at the American Academy of Neurology meeting. While the study failed to find a definitive benefit for its two main goals, a third analysis favored by U.S. regulators showed patients had 26 percent to 35 percent fewer seizures over 28 days on perampanel, compared with 21 percent in those on a placebo, said Jacqueline French, director of the clinical trials consortium at New York University’s epilepsy center.

Read at News Release
Read at WebMD
Read at Bloomberg

comments powered by Disqus
   
Epilepsy

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES